Weekly in Asia|Oct
20191006-1012 Weekly in Asia BioJapan 2019 Boosts Japan’s New Bioeconomy Strategy BioJapan 2019 was launched on October 10th at the Pacifico Yokohama convention plaza for three days, over 1,000 organizations …
Read MoreThe Next Generation Biotech Media
20191006-1012 Weekly in Asia BioJapan 2019 Boosts Japan’s New Bioeconomy Strategy BioJapan 2019 was launched on October 10th at the Pacifico Yokohama convention plaza for three days, over 1,000 organizations …
Read More20190728-0803 Weekly in Asia CUHK to Launch GMP-certified CAR-T Cell Therapy Laboratory for Haematological Malignancy Cancer is one of the leading causes of mortality globally. According to estimations, there is an average of …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. Three years since launching BlueRock Therapeutics with a $225 million series A funding, Bayer and Versant Ventures are once again firmly investing in stem cell …
Read MoreJapan Approves Roche’s Personalized Cancer Drug Rozlytrek Tyrosine receptor kinase (TRK) A/B/C and ROS1 proteins activates fusions that drive proliferation in certain types of solid tumor, including pancreatic, thyroid, salivary …
Read More2018 Nobel laureate Tasuku Honjo to Lead Japan’s First Cancer Immunotherapy Research Center In 1992, Tasuku Honjo, a professor of molecular immunology at Kyoto University, identified programmed cell death protein …
Read MoreBy Rajaneesh K Gopinath The youngster from Watford was treated with the immunotherapy agent, Kymriah to counter a form of cancer that he has been battling for years. Yuvan Thakkar …
Read MoreBIO ASIA-Taiwan 2019 – A reflection of Taiwan’s growing stature within the global biotech community 15 January, 2019 // Taipei, Taiwan The global Biotechnology Innovation Organization (BIO) together with the …
Read MoreBy Rajaneesh K. Gopinath, Ph.D. Proudly co-organized by GeneOnline, the global biotech conference brings key opinion leaders comprising healthcare professionals and technology giants under one roof promoting scientific exchange and …
Read MoreBy Ajay V. Patil With whopping $300 million in series-A funding, Allogene therapeutics quickly raised additional $100 million to become a blockbuster biotech IPO. We summarize its inception and development …
Read MoreFrom AIoT, Blockchain, Gene Editing, Cell Therapy, to Immune-Oncology, MEDTEX brings over 30 cross-industry global key opinion leaders to Taipei. MEDTEX welcomes world-renowned experts Including Microsoft, Google AI, Takeda, Mayo …
Read More